Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT Jr+ long-term safety study of intravenous and subcutaneous efgartigimod in children with generalized myasthenia gravis
NL-OMON60193Phase 3Recruiting
- Sponsor
- argenx
- Start
- Dec 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (2 arms), sponsored by argenx. Primary endpoints: Incidence and severity of adverse events, Incidence and severity of serious adverse events and 2 more. Started Dec 2022; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON60193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60193.